Heron Therapeutics Inc (NAS:HRTX)
$ 3.5799 0.2699 (8.15%) Market Cap: 539.33 Mil Enterprise Value: 608.55 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

Heron Therapeutics Inc to discuss the Complete Response Letter - Conference Call Transcript

May 01, 2019 / 12:30PM GMT
Release Date Price: $17.75 (-18.13%)
Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

Now I'd like to turn the call over to David Szekeres, Senior Vice President, General Counsel Business Development and Corporate Secretary. Please proceed.

David L. Szekeres
Heron Therapeutics, Inc. - Senior VP of Business Development, General Counsel & Corporate Secretary

Thank you, Kevin. Good morning, everyone, and thank you for joining us. With me today from Heron are Barry Quart, President and Chief Executive Officer; Kimberly Manhard, Executive Vice President of Drug Development; and Mike Mathews, Senior Vice President of Pain Franchise.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Heron's future expectations, plans, prospects, corporate strategy and performance, which constitute forward looking statements for the purposes of the Safe Harbor provision under the Private Securities

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot